Renal injury in cardiorenal syndrome type 1 is mediated by albumin

Funahashi, Yasuyuki; Ikeda, Makoto; Wakasaki, Rumie; Chowdhury, Shiuly; Groat, Tahnee; Zeppenfeld, Douglas; Hutchens, Michael P.

doi:10.14814/phy2.15173

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kidney disease progression is actually slower in albumin knockout mice than wild-type mice [ 46 ]. Albuminuria is commonly noted in severe renal disease, and in such cases albumin may promote apoptosis of the tubular epithelial cells, leading to the progressive worsening of the pathology [ 47 ]. While it is generally believed that albumin has antioxidant and antiinflammatory roles in the body, it is also true that it can propagate the detriments of oxidative stress through the effects of chemically modified albumin upon cells.…”

Section: Discussionmentioning

confidence: 99%

Alterations in the Plasma Protein Expression Pattern in Congenital Analbuminemia—A Systematic Review

2023

View full text Add to dashboard Cite

Albumin is a highly abundant plasma protein with multiple functions, including the balance of fluid between body compartments and fatty acid trafficking. Humans with congenital analbuminemia (CAA) do not express albumin due to homozygosity for albumin gene mutation. Lessons about physiological control could be learned from CAA. Remarkably, these patients exhibit an apparently normal lifespan, without substantial impairments in physical functionality. There was speculation that tolerance to albumin deficiency would be characterized by significant upregulation of other plasma proteins to compensate for analbuminemia. It is unknown but possible that changes in plasma protein expression observed in CAA are required for the well-documented survival and general wellness. A systematic review of published case reports was performed to assess plasma protein pattern remodeling in CAA patients who were free of other illnesses that would confound interpretation. From a literature search in Pubmed, Scopus, and Purdue Libraries (updated October 2022), concentration of individual plasma proteins and protein classes were assessed. Total plasma protein concentration was below the reference range in the vast majority of CAA patients in the analysis, as upregulation of other proteins was not sufficient to prevent the decline of total plasma protein when albumin was absent. Nonetheless, an impressive level of evidence in the literature indicated upregulated plasma levels of multiple globulin classes and various specific proteins which may have metabolic functions in common with albumin. The potential role of this altered plasma protein expression pattern in CAA is discussed, and the findings may have implications for other populations with hypoalbuminemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Alterations in the Plasma Protein Expression Pattern in Congenital Analbuminemia—A Systematic Review

2023

View full text Add to dashboard Cite

show abstract

“…Reducing of urinary albumin is a biomarker of early improvement in T2-CRS after CRT (Gala-Błądzińska et al, 2020). Funahashi et al (2022) suggested that improving CRS-1 outcomes might be possible through albumin resuscitation. MI-induced CRS in rats accelerates glomerular remodeling and the production of trace albuminuria (Dong et al, 2015).…”

Section: Existing Biomarkers In Crsmentioning

confidence: 99%

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Zhang,

Zhu,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethylamine (TMA) that is produced by the gut microbiota after consumption of carnitine and choline and is then transformed by flavin-containing monooxygenase (FMO) in the liver. Numerous research results have shown that TMAO not only participates in the pathophysiological progression of heart and renal diseases but also significantly affects outcomes in chronic heart failure (CHF) and chronic kidney disease (CKD), besides influencing the general health of populations. Elevated circulating TMAO levels are associated with adverse cardiovascular events such as HF, myocardial infarction, and stroke, patients with CKD have a poor prognosis as well. However, no study has confirmed an association between TMAO and cardiorenal syndrome (CRS). As a syndrome in which heart and kidney diseases intersect, CRS is often overlooked by clinicians. Here, we summarize the research on TMAO in HF and kidney disease and review the existing biomarkers of CRS. At the same time, we introduced the relationship between exercise and gut microbiota, and appropriately explored the possible mechanisms by which exercise affects gut microbiota. Finally, we discuss whether TMAO can serve as a biomarker of CRS, with the aim of providing new strategies for the detection, prognostic, and treatment evaluation of CRS.

show abstract

“…The presence of albuminuria as an essential factor in staging the severity of CKD is the result of several large population studies showing strong significant correlation between albuminuria and all-cause mortality, cardiovascular disease, and end stage renal disease (39)(40)(41). Recent in vitro studies of a type I CRS model using human kidney cells have demonstrated that albumin damages renal tubules in a dose-dependent fashion, thereby implicating it as an important pathophysiological factor further exacerbating AKI in experimental conditions (42). Albuminuria has been studied as a disease prognosis marker in both acute and chronic heart failure as well.…”

Section: Albuminuriamentioning

confidence: 99%

Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes

Prkačin,

Delalić,

Brežni

2023

Biochem. med. (Online)

View full text Add to dashboard Cite

Cardiorenal syndrome (CRS), first defined in 2004 as a consequence of the interactions between the kidneys and other circulatory departments leading to acute heart failure, has since been recognized as a complex clinical entity that is hard to define, diagnose and classify. The framework for the classification of CRS according to pathophysiologic background was laid out in 2008, dividing CRS into five distinct phenotypes. However, determining the timing of individual organ injuries and making a diagnosis of either renal or cardiac failure remains an elusive task. In clinical practice, the diagnosis and phenotyping of CRS is mostly based on using laboratory biomarkers in order to directly or indirectly estimate the degree of end-organ functional decline. Therefore, a well-educated clinician should be aware of the effects that the reduction of renal and cardiac function has on the diagnostic and predictive value and properties of the most commonly used biomarkers (e.g. troponins, N-terminal pro-brain natriuretic peptide, serum creatinine etc). They should also be acquainted, on a basic level, with emerging biomarkers that are specific to either the degree of glomerular integrity (cystatin C) or tubular injury (neutrophil gelatinase-associated lipocalin). This narrative review aims to provide a scoping overview of the different roles that biomarkers play in both the diagnosis of CRS and the prognosis of the disease in patients who have been diagnosed with it, along with highlighting the most important pitfalls in their interpretation in the context of impaired renal and/or cardiac function.

show abstract

Renal injury in cardiorenal syndrome type 1 is mediated by albumin

Cited by 4 publications

References 28 publications

Alterations in the Plasma Protein Expression Pattern in Congenital Analbuminemia—A Systematic Review

Alterations in the Plasma Protein Expression Pattern in Congenital Analbuminemia—A Systematic Review

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes

Contact Info

Product

Resources

About